CWRU

AlensiaXR Series A Funding Round to Evolve Anatomical Instruction Using Holograms

Retrieved on: 
Thursday, February 1, 2024
Health Technology, Start-Up, Technology, University, Finance, Education, Apps, Applications, Professional Services, General Health, Artificial Intelligence, Science, Software, Other Science, Health, Research, CWRU, Growth, Case Western Reserve University, Anatomy, Physiology, Faculty, Dissection, Pathology, Investment, Microsoft HoloLens, Learning, Doctor of Philosophy, Student, Series, Finger Lakes Community College, Cadaver, Management

AlensiaXR, a technology company launched by Case Western Reserve University (CWRU), today announced the completion of its Series A funding round to accelerate development and delivery of its HoloAnatomy® learning platform.

Key Points: 
  • AlensiaXR, a technology company launched by Case Western Reserve University (CWRU), today announced the completion of its Series A funding round to accelerate development and delivery of its HoloAnatomy® learning platform.
  • The software revolutionizes anatomical instruction by leveraging advanced holographic technology, reducing the need for costly, resource-intensive cadaver labs.
  • “This milestone marks a significant step forward in the transformation of medical education,” said AlensiaXR CEO Mark Day, who previously led Microsoft’s global HoloLens business.
  • “HoloAnatomy redefines anatomical instruction,” said Mark Griswold, professor at the CWRU School of Medicine and faculty director at the university’s Interactive Commons, which developed the software.

California State Treasurer, Fiona Ma, and US-India cross-border association, AllianceIndus, congratulate Hemex Health for India partnerships that led to a breakthrough test for sickle cell disease

Retrieved on: 
Wednesday, October 18, 2023
Hemoglobinopathy, SCD, Organizational founder, Reading, Ship, CWRU, Sickle cell disease, Case Western Reserve University, Beta thalassemia, Woman, SAN, Medical device

The Hemex Diagnostic Platform, Gazelle™, supports a powerful test for hemoglobinopathies including SCD and beta thalassemia and was launched into the Indian market in early 2021.

Key Points: 
  • The Hemex Diagnostic Platform, Gazelle™, supports a powerful test for hemoglobinopathies including SCD and beta thalassemia and was launched into the Indian market in early 2021.
  • It is manufactured in India and currently ships from India to over 30 countries.
  • “Hemex utilized invention from Case Western Reserve University (CWRU), Hemex’s experience in low-cost design, and India’s competitive manufacturing.
  • This winning combination will help us realize our vision of improving access to accurate testing.”
    Please click here to continue reading.

ArteraAI Announces First-Ever AI-Derived Biomarker for Predicting Androgen Deprivation Therapy (ADT) Benefit in Prostate Cancer

Retrieved on: 
Thursday, June 29, 2023
Technology, Men, Health, Biometrics, Consumer, Artificial Intelligence, Oncology, Other Science, Other Technology, Research, Medical Devices, General Health, Science, Clinical Trials, University, The New England Journal of Medicine, University of California, San Francisco, University Hospitals Cleveland Medical Center, Radiation, ADT, Prostate, CWRU, Radiation therapy, NEJM, MD, Patient, Disease, AI, Urology, Medicine, Prostate cancer, Medical imaging

ArteraAI , the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announced today the publication of data in the NEJM Evidence, validating the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer.

Key Points: 
  • ArteraAI , the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announced today the publication of data in the NEJM Evidence, validating the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer.
  • In past U.S.-based clinical trials, African American men have made up only 10.8% of prostate cancer trial participants .
  • If given the opportunity to leverage the biomarker, most intermediate-risk patients could potentially avoid the morbidity and financial burden associated with ADT.
  • We celebrate this achievement while also looking ahead to how we can build upon this evidence to continue transforming care for men diagnosed with localized prostate cancer.”
    For more information on ArteraAI, visit Artera.ai .

Praxis Spinal Cord Institute Adds Five Leaders to Board

Retrieved on: 
Tuesday, June 27, 2023
Spaulding Rehabilitation Hospital, Emergency medicine, Tetraplegia, Disability, Physician, Praxis, Quality of life, Woman, MetroHealth, Boston, Research, CWRU, Person, Translation, Science, Pan American Games, Paralysis, Organization, Boston Police Department, EMS, Mattel, Medical director, Admission, School, Surgeon, MA, Foothills Medical Centre, SCI, Cumming School of Medicine, Chair, Medical device, Management, Paralympic Games, Medicine

Vancouver, BC, June 27, 2023 (GLOBE NEWSWIRE) -- VANCOUVER, BC – June 27, 2023 – The appointment of five new members to the Praxis Spinal Cord Institute Board of Directors brings outstanding experience in advocacy, clinical research, communications and governance to the board.

Key Points: 
  • Vancouver, BC, June 27, 2023 (GLOBE NEWSWIRE) -- VANCOUVER, BC – June 27, 2023 – The appointment of five new members to the Praxis Spinal Cord Institute Board of Directors brings outstanding experience in advocacy, clinical research, communications and governance to the board.
  • Their oversight and experience strengthens our impact, focusing our unique Praxis model on engaging with people with lived experience of spinal cord injury (SCI).
  • Praxis is a Vancouver, BC-based not-for-profit organization that leads global collaboration in spinal cord injury research, innovation, and care.
  • She is currently the Director of the Northeast Ohio Regional Spinal Cord Injury Model System of Care, and was a co-founder and the inaugural President of the North American Spinal Cord Injury Consortium.

ADEA Announces 2023-24 Fellows of Its Inaugural Council of Deans Fellowship

Retrieved on: 
Wednesday, June 21, 2023
Health, Other Education, University, Dental, Education, Archives of Oral Biology, Experimental pathology, DRS, CWRU, Maryland School, Chemistry, Fellows, Research, Postgraduate education, CODA, Al-Ghad International Health Sciences Colleges, Prosthodontics, Exhibition, M.A, Indiana University School of Dentistry, Harvard School of Dental Medicine, Dean (education), Oral medicine, Pathology, Case Western Reserve University School of Medicine, Oral and maxillofacial pathology, Sacroiliac joint, University of Siena, ADEA, Western University, American Academy, Association of Christian Universities and Colleges in Asia, Otorhinolaryngology, Diplom, University of Maryland School of Dentistry, Dentistry, New York University, Orofacial pain, Medicine

ADEA is pleased to announce the inaugural class of the ADEA Council of Deans Fellowship (ADEA CDF), a new leadership development program that launched in May.

Key Points: 
  • ADEA is pleased to announce the inaugural class of the ADEA Council of Deans Fellowship (ADEA CDF), a new leadership development program that launched in May.
  • The ADEA CDF is a year-long, part-time fellowship aimed at creating a diverse pipeline of future leaders who will assume roles as dental school deans and other senior university leadership positions.
  • The ADEA CDF will increase the number of qualified candidates for deanships and equip them with the skills and experiences to help them succeed.
  • The ADEA CDF Program Director is Dean Emeritus Steven Friedrichsen, D.D.S., of Western University of Health Sciences College of Dental Medicine.

Artera Announces Positive Results Around Its Multimodal Artificial Intelligence (MMAI) Prognostic Biomarker

Retrieved on: 
Thursday, February 16, 2023
Research, Technology, Medical Devices, Clinical Trials, Health Technology, General Health, Health, Science, Oncology, Artificial Intelligence, CWRU, III, Prostate cancer, Prognosis, MMAI, Radiation, Patient, AI, University Hospitals Cleveland Medical Center, ASCO, Medical imaging

Artera , the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announced new data today at ASCO GU 2023 demonstrating that its multimodal artificial intelligence (MMAI) prognostic biomarker can help bring more personalized treatment to men with localized prostate cancer.

Key Points: 
  • Artera , the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announced new data today at ASCO GU 2023 demonstrating that its multimodal artificial intelligence (MMAI) prognostic biomarker can help bring more personalized treatment to men with localized prostate cancer.
  • The biomarker was successfully validated across six phase III randomized trials with long-term follow-up to be independently prognostic over standard clinical and pathologic variables for men with high-risk prostate cancer.
  • The AI combines those two pieces of information to predict a patient’s prognosis and how the patient may respond to a particular treatment.
  • The algorithm has been trained on large amounts of data, from tens of thousands of patients and hundreds of thousands of pathology slide images.

NEW RESEARCH PAPER SUPPORTS USING MICROBIOME DATA TO DEVELOP POTENTIAL PROBIOTIC THERAPIES

Retrieved on: 
Thursday, January 26, 2023
Spectrum, Fungus, Human Microbiome Project, CWRU, Case Western Reserve University, Overalls, UH, Bangladesh Technical Education Board, Human, Health, National Institutes of Health, Cardiovascular disease, Environment, Maintenance, Volunteering, Medical Mycology, Obesity, Flatulence, Probiotic, Dysbiosis, Trial of the century, University Hospitals Cleveland Medical Center, Absorption, Bloating, Research, Cancer, Growth, Mouse, Constipation, Diabetes, Microbiome, CD, Bacteria, Crohn's disease, Chronic pain, HMP, Disease, Irritability, Biofilm, Anxiety, Metadata, Doctor of Philosophy, Mycology, Medical device, Dietary supplement, Gum arabic, Sewage treatment, Antibiotics, Tourism, Medicine, Dermatology, Gastroenterology

CLEVELAND, Jan. 26, 2023  /PRNewswire/ -- In a new paper, published Jan. 25, 2023, online by the journal Gastroenterology, researchers from University Hospitals (UH) Cleveland Medical Center and Case Western Reserve University School of Medicine, review studies about the microbiome's role in disease and health, and discuss tactics for developing probiotics to modulate the microbiome through leveraging microbiome data. They illustrate these tactics by using Crohn's disease (CD) as an example.

Key Points: 
  • The comprehensive intestinal microbiome, representing bacterial and fungal communities, profiles were assessed at the start of the study and following four weeks of probiotic consumption.
  • Through the analysis of big microbiome data sets, researchers have started to appreciate the microbiome composition differences between different cohorts of individuals.
  • That has lead to the opportunity to leverage such data insights for targeted microbiome solution development.
  • The probiotic formulation developed through this data-powered design process was launched in market by BIOHM Health Inc. as a general wellness probiotic.

PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome

Retrieved on: 
Wednesday, January 18, 2023
Disease, CWRU, Case Western Reserve University, Mental health, Depression, Laboratory, School, Rett syndrome, FDA, Ketamine, Marketing, Medical school, X chromosome, Orphan Drug Act of 1983, Disorder, BDNF, Orphan drug, GABAergic, Female, MECP2, Pharmaceutical industry, Rett, Medicine

According to the Rett Syndrome Foundation, Rett syndrome is a rare genetic neurological disorder that occurs almost exclusively in girls.

Key Points: 
  • According to the Rett Syndrome Foundation, Rett syndrome is a rare genetic neurological disorder that occurs almost exclusively in girls.
  • Prominent features of Rett syndrome include near constant repetitive hand movements and loss of purposeful hand use.
  • The Orphan Drug Act grants special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor.
  • The FDA grants orphan status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.

Folio Photonics to Showcase Advancements in First-Ever Enterprise-Scale, Optical Data Storage Solution at CES 2023

Retrieved on: 
Tuesday, December 27, 2022
HDD, Case Western Reserve University, CO2, Ambrose Swasey, Engineering, DVD, Hard disk drive performance characteristics, TB, CES, Blu-ray, Science, TCO, Sustainability, CWRU, Computer data storage, Folio, Santamaria, Physics

SOLON, Ohio, Dec. 27, 2022 /PRNewswire-PRWeb/ -- Folio Photonics today announced it will showcase how it is reenergizing data storage media innovation with the first-ever enterprise-scale, optical disc data storage solution that delivers breakthrough cost, margin, performance and sustainability benefits at next week's CES 2023, taking place January 5-8, 2023 (Las Vegas, NV).

Key Points: 
  • CES Attendees to See How Folio Photonics' Next-Gen Data Storage Radically Reduces Upfront Cost and TCO While Making Data Archives Active, Cybersecure, Performant and Sustainable
    SOLON, Ohio, Dec. 27, 2022 /PRNewswire-PRWeb/ -- Folio Photonics today announced it will showcase how it is reenergizing data storage media innovation with the first-ever enterprise-scale, optical disc data storage solution that delivers breakthrough cost, margin, performance and sustainability benefits at next week's CES 2023 , taking place January 5-8, 2023 (Las Vegas, NV).
  • Folio Photonics and its licensed technology were spun-off from CWRU and its National Science Foundation Center for Layered Polymeric Systems by Dr. Kenneth Singer.
  • Ideal for data center and hyperscale customers, Folio's next-generation data storage media radically reduces upfront cost and TCO while making data archives active, cybersecure, performant, and sustainable.
  • Folio Photonics is reenergizing storage media innovation with the first-ever enterprise-scale, optical data storage solution.

Another Year, Another Weatherhead 100 Award Win for CLEANLIFE®

Retrieved on: 
Thursday, December 22, 2022
The Coca-Cola Company, Engineering, IOT, Walmart, Case Western Reserve University, GE Lighting, Valley View, Lighting, Growth, Microsoft, Marriott International, Fortune 500, Lowes, Entrepreneurship, Wendy's, PepsiCo, Multimedia, LED, Alumnus, The Home Depot, Wynn Resorts, ExxonMobil, Smart lighting, CWRU, Bottled water, Amazon, IHG

This award is a crowning achievement for another successful year operating as a business in Northeast Ohio.

Key Points: 
  • This award is a crowning achievement for another successful year operating as a business in Northeast Ohio.
  • The Weatherhead 100 recognizes the fastest growing companies in Northeast Ohio.
  • "Established in 1988, The Weatherhead 100 awards are the premier celebration of Northeast Ohio's spirit of entrepreneurship and the companies leading the way in Northeast Ohio.
  • I am honored to be part of an organization that has been regularly recognized as a Weatherhead 100 winner, as an award presented by my alma mater."